EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)

Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low–Tumor Burden Follicular Lymphoma: Results of a LYSA Study

Guillaume Cartron iD, Emmanuel Bachy iD, Hervé Tilly iD, Nicolas Daguindau, Gian-Matteo Pica, Fontanet Bijou iD, Christiane Mounier, Aline Clavert, Gandhi Laurent Damaj iD, Borhane Slama, Olivier Casasnovas iD, Roch Houot iD und 19 weitere

Journal of Clinical Oncology · 01.07.2023 · 41 (19) · 3523-3533

DOI: 10.1200/jco.22.02327 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 01.07.2023. Verfasst von Guillaume Cartron und 30 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, UMR CNRS 5535, University Hospital, Montpellier, France. Hauptthemen laut MEDLINE: Lymphoma, Follicular. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Rituximab improves progression-free survival (PFS) and time to next treatment (TTNT) when compared with the watch and wait strategy for patients with low–tumor burden follicular lymphoma (FL). Prolonged rituximab maintenance did not prolong TTNT, whereas it raises concerns about resources use and patient adhesion. Our aim was then to investigate the use of short rituximab maintenance using the subcutaneous (SC) route in patients with low–tumor burden FL. METHODS Patients with histologically confirmed CD20 + low–tumor burden FL were randomly assigned to receive either rituximab, 375 mg/m 2 once daily on D1, D8, D15, and D22, intravenous route (IV, control arm), or rituximab, 375 mg/m 2 , on day 1 (D1), IV followed by rituximab 1,400 mg total dose, SC once daily on D8, D15, and D22, with maintenance at months 3 (M3), M5, M7, and M9 (experimental arm). The primary end point was PFS. Secondary end points included safety, overall response rates, TTNT, and overall survival (OS). RESULTS Two hundred two patients with low–tumor burden FL were randomly assigned to the experimental (n = 100) or control arm (n = 102). The primary end point was met: the 4-year PFS was 58.1% (95% CI, 47.5 to 67.4) and 41.2% (95% CI, 30.6 to 51.6) in experimental and control arms, respectively (hazard ratio, 0.585 [0.393 to 0.871]; P = .0076). Complete response (CR) rates were 59.0% (95% CI, 48.7 to 68.7) in the experimental arm and 36.3% (95% CI, 27.0 to 46.4) in the control arm ( P = .001). TTNT and OS were not significantly different. CR was associated with longer PFS and TTNT. High rituximab exposure during the first three months was independently associated with higher CR, PFS, and TTNT. CONCLUSION SC rituximab improves PFS for patients with low–tumor burden FL when used in induction followed by short maintenance. High rituximab exposure during the first 3 months after treatment initiation is, however, the only parameter influencing patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, FollicularHumansRituximabTumor BurdenAntineoplastic Combined Chemotherapy ProtocolsProgression-Free Survival

Substanzen

Rituximab

Autor:innen und Institutionen

  • Department of Hematology, UMR CNRS 5535, University Hospital, Montpellier, France.
  • Department of Hematology, University Hospital, Lyon, France.
  • Department of Hematology, U1245, Henri Becquerel Institute, Rouen, France.
  • Departement of Hematology, Annecy-Genevois Hospital Centre, Annecy, France.
  • Departement of Hematology, Hospital Centre, Chambery, France.
  • Departement of Hematology, Bergonié Institute, Bordeaux, France.

ORCID-Profile: Guillaume Cartron, Emmanuel Bachy, Hervé Tilly, Fontanet Bijou, Gandhi Laurent Damaj, Olivier Casasnovas, Roch Houot, David Sibon, Nadine Morineau, Charles Herbaux, Luc-Matthieu Fornecker, Vincent Launay, Laurence Sanhes, Hugo Gonzalez, Franck Morschhauser

Zitieren

APA

Cartron, G., Bachy, E., Tilly, H., Daguindau, N., Pica, G. M., Bijou, F., Mounier, C., Clavert, A., Damaj, G. L., Slama, B., Casasnovas, O., Houot, R., Bouabdallah, K., Sibon, D., Fitoussi, O., Morineau, N., Herbaux, C., Gastinne, T., Fornecker, L. M., …, & Pranger, D. (2023). Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low–Tumor Burden Follicular Lymphoma: Results of a LYSA Study. Journal of Clinical Oncology, 41(19), 3523-3533. https://doi.org/10.1200/jco.22.02327

Vancouver

Cartron G, Bachy E, Tilly H, Daguindau N, Pica GM, Bijou F, et al. Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low–Tumor Burden Follicular Lymphoma: Results of a LYSA Study. Journal of Clinical Oncology. 2023;41(19):3523-3533. doi:10.1200/jco.22.02327

BibTeX
@article{Cartron2023,
  author = {Cartron, Guillaume and Bachy, Emmanuel and Tilly, Hervé and Daguindau, Nicolas and Pica, Gian-Matteo and Bijou, Fontanet and Mounier, Christiane and Clavert, Aline and Damaj, Gandhi Laurent and Slama, Borhane and Casasnovas, Olivier and Houot, Roch and Bouabdallah, Krimo and Sibon, David and Fitoussi, Olivier and Morineau, Nadine and Herbaux, Charles and Gastinne, Thomas and Fornecker, Luc-Matthieu and Haioun, Corinne and Launay, Vincent and Araujo, Carla and Benbrahim, Omar and Sanhes, Laurence and Gressin, Remy and Gonzalez, Hugo and Morschhauser, Franck and Ternant, David and Xerri, Luc and Tarte, Karin and Pranger, Delphine},
  title = {Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low–Tumor Burden Follicular Lymphoma: Results of a LYSA Study},
  journal = {Journal of Clinical Oncology},
  year = {2023},
  volume = {41},
  number = {19},
  pages = {3523--3533},
  doi = {10.1200/jco.22.02327}
}
Kostenlos starten →